Filing Flows › Interpace Biosciences (IDXG) › Q4 2025
Interpace Biosciences (IDXG) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Interpace Biosciences (IDXG) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and +5% from the quarter before. Operating margin was 17.1%, net earnings $22.7M (245.6% of revenue).
Interpace Biosciences, Q4 2025: revenue $9.2M (-26% year over year), operating margin 17.1%, net earnings $22.7M, operating cash flow $2.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | +5% | -26% |
| Gross profit | $6.0M | +11% | -24% |
| Operating profit | $1.6M | +38% | -23% |
| Net earnings | $22.7M | 25× | 12× |
| Operating cash flow | $2.1M | +10% | +81% |
| Free cash flow | $2.1M | +15% | +99% |
What changed
Revenue was $9.2M in Q4 2025, down 26% year over year and up 5% from the previous quarter.
Gross margin was 65.5%, up 1.8 points from Q4 2024. Operating profit was $1.6M, a 17.1% margin (up 0.5 points year over year). Operating expenses fell 24% while revenue fell 26%. Net earnings were $22.7M, up 1105% year over year. The tax line was a benefit of $21.2M on pre-tax earnings of $1.4M.
Operating cash flow was $2.1M (up 81% year over year), 9% of net earnings. Non-cash charges added back $118K of depreciation and amortization and $4K of share-based compensation. Working capital and other items used $20.6M. Capital expenditures of $38K left free cash flow of $2.1M.
Questions
What was Interpace Biosciences' revenue in the fourth quarter 2025?
Interpace Biosciences (IDXG) reported revenue of $9.2M for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and +5% from the quarter before.
Was Interpace Biosciences profitable in the fourth quarter 2025?
Operating profit was $1.6M (17.1% of revenue) and net earnings $22.7M.